S9715, Study of Patients With Advanced Nasopharyngeal Cancers Treated With Chemo-Radiotherapy, Phase II
OBJECTIVES: I. Gather additional information and experience regarding the preferred
treatment from clinical trial SWOG-8892, chemoradiation for patients with advanced
nasopharyngeal cancers (NPC). II. Evaluate survival and progression-free survival and
patterns of tumor failure in this new group of patients. III. Assess severe or lethal
toxicities that may be encountered after this regimen is employed more widely. IV. Collect
NPC tumor specimens for ongoing and future clinical correlative research.
OUTLINE: Patients receive cisplatin by intravenous infusion on day 1 over a 15-20 minute
period. This is repeated every 21 days for the first three initial treatments. Patients also
receive radiation therapy once daily five times a week during this cycle of treatment.
Approximately three weeks after completion of the above treatment, patients are given
cisplatin by intravenous infusion over 15-20 minutes as above but at a lower dose. On the
same day as cisplatin infusion, patients receive fluorouracil by continuous intravenous
infusion over 24 hours for 4 days in a row. This is repeated every 28 days for a total of 3
treatments. Patients are followed until death.
PROJECTED ACCRUAL: 100 patients will be accrued.
Primary Purpose: Treatment
Muhyi Al-Sarraf, MD
Providence Cancer Institute at Providence Hospital - Southfield Campus
United States: Food and Drug Administration